Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - Vertex Pharmaceuticals Newsroom

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

You will be redirected in 10 seconds.